10:49 AM EDT, 05/08/2024 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday that Health Canada has approved an expanded indication for Qulipta to include preventive treatment of chronic migraine in adults.

With the expanded indication, the drug is now approved for both episodic and chronic migraine, the company said.

The expanded indication was based on the pivotal phase 3 trial that assessed Qulipta 60 milligrams once a day in adults with chronic migraine, which met its primary endpoint of statistically significant reduction in mean monthly migraine days, AbbVie ( ABBV ) said.

Price: 160.35, Change: -2.20, Percent Change: -1.35